Celanese Earnings Call Transcripts
Fiscal Year 2026
-
Q2 supply-chain agility and EM pricing supported results, while Lanaken absorption and raw-material inflation weigh on Q3. FY earnings guidance remains ~$6 and free cash flow guidance $700 million-$800 million, with cost reductions and deleveraging priorities continuing.
-
Q1 saw strong asset utilization and flexible operations amid weak demand and supply chain disruptions. H2 guidance assumes moderate recovery as supply chains normalize, with upside if current conditions persist. Strategic cost actions and targeted growth in Engineered Materials continue.
-
The meeting covered director elections, auditor ratification, and executive compensation approval, with all proposals passing by majority vote. No additional shareholder proposals were introduced, and no questions were received during the Q&A session.
Fiscal Year 2025
-
Cash generation and cost reduction remain top priorities, with $650M–$750M free cash flow targeted for 2026. Engineered Materials is expected to drive growth, while Acetyl Chain faces margin pressure from overcapacity, especially in China. Divestitures and operational efficiencies support deleveraging.
-
Priorities for 2026 are cost improvements, cash flow, and top-line growth, with $1-$2 EPS uplift expected even if demand stays flat. Free cash flow is guided at $700M–$800M, and portfolio optimization continues with divestitures and cost actions.
-
Order books weakened in June and July, with demand softness in China automotive, European EM, and Western Hemisphere acetyls. Q3 EPS guidance is $1.25, with a $2 per share target achievable through cost actions and business model execution, though timing may be delayed if demand remains weak.
-
Management is focused on EPS growth, free cash flow, and aggressive deleveraging, with Q2 guidance on track and cost savings targets raised. Asset divestitures and working capital reductions are key to accelerating debt reduction, while specialty and high-value projects drive business segment strategy.
-
Management is focused on cash generation, cost reduction, and portfolio optimization amid ongoing demand uncertainty. Free cash flow is guided at $700–$800 million for 2025, with operational flexibility and self-help actions supporting earnings. Demand volatility and overcapacity, especially in nylon and acetyls, remain key risks.
Fiscal Year 2024
-
Management is prioritizing cash generation, cost reduction, and deleveraging through targeted divestitures, reduced CapEx, and operational improvements. Free cash flow and EBITDA are expected to improve in 2025, with a focus on margin recovery and growth in high-value segments.
-
Q3 results fell short amid persistent macro headwinds, prompting a temporary dividend cut and aggressive cost actions to support deleveraging. Outlook for Q4 and 2025 remains cautious, with demand recovery uncertain and further cost discipline planned.
-
Q3 and Q4 outlooks are based on stable macro conditions, with moderate auto growth and largest synergy capture expected in Q4. Force majeure and supply chain disruptions impacted productivity, but integration synergies and cost controls are driving margin expansion. Debt reduction and lower CapEx support improved cash flow.